This article describes the results of a preclinical safety and immunogenicity study of
QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats …

The present study provides the first information about the protection of a novel influenza viral
vector vaccine expressing the Brucella proteins ribosomal L7/L12 or Omp16 containing the …

Previously we developed and evaluated a candidate influenza viral vector based Brucella
abortus vaccine (Flu-BA) administered with a potent adjuvant Montanide Gel01 in cattle …

Influenza virus infections pose a continuous threat to human health. Although vaccines
function as a preventive and protective tool, they may not be effective due to antigen drift or …

Creating an effective and safe vaccine is critical to fighting the coronavirus infection
successfully. Several types of COVID-19 vaccines exist, including inactivated, live …

This study analyzed the duration of the antigen-specific humoral and T-cell immune
responses and protectiveness of a recently-developed influenza viral vector Brucella …

This paper describes a preclinical study analyzing the immunogenicity and protective
efficacy of Kazfluvac®, an adjuvant-based inactivated pandemic influenza A/H5N1 virus …

Pandemic influenza A virus (H1N1) 2009 poses a serious public-health challenge
worldwide. To characterize the neutralizing epitopes of this virus, we generated a panel of …

The present study provides the first information about the safety of a new influenza viral
vector vaccine expressing the Brucella ribosomal protein L7/L12 or Omp16 containing the …

Аннотация This study looks into optimal conditions for cultivating the recombinant strains of
subtype H5 influenza virus. The study results in establishing optimal conditions (inoculation …